Find Cenobamate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Xcopri, 913088-80-9, Cenobamate [inn], Ykp3089, Ykp-3089, P85x70rzws
Molecular Formula
C10H10ClN5O2
Molecular Weight
267.67  g/mol
InChI Key
GFHAXPJGXSQLPT-VIFPVBQESA-N
FDA UNII
P85X70RZWS

Cenobamate
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
1 2D Structure

Cenobamate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
[(1R)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] carbamate
2.1.2 InChI
InChI=1S/C10H10ClN5O2/c11-8-4-2-1-3-7(8)9(18-10(12)17)5-16-14-6-13-15-16/h1-4,6,9H,5H2,(H2,12,17)/t9-/m0/s1
2.1.3 InChI Key
GFHAXPJGXSQLPT-VIFPVBQESA-N
2.1.4 Canonical SMILES
C1=CC=C(C(=C1)C(CN2N=CN=N2)OC(=O)N)Cl
2.1.5 Isomeric SMILES
C1=CC=C(C(=C1)[C@H](CN2N=CN=N2)OC(=O)N)Cl
2.2 Other Identifiers
2.2.1 UNII
P85X70RZWS
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Carbamate (ester), (alphar)-

2. Carbamic Acid (r)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Ester

3. Xcopri

4. Ykp-3089

5. Ykp3089

2.3.2 Depositor-Supplied Synonyms

1. Xcopri

2. 913088-80-9

3. Cenobamate [inn]

4. Ykp3089

5. Ykp-3089

6. P85x70rzws

7. [(1r)-1-(2-chlorophenyl)-2-(tetrazol-2-yl)ethyl] Carbamate

8. Carbamic Acid (r)-(+)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Ester

9. Ontozry

10. Unii-p85x70rzws

11. Xcopri (tn)

12. Cenobamate [mi]

13. Ykp-3089 Cenobamate

14. Cenobamate (usan/inn)

15. Cenobamate [usan:inn]

16. Cenobamate [usan]

17. Cenobamate [who-dd]

18. Schembl1682643

19. Cenobamate [orange Book]

20. Chembl3989949

21. Gtpl10773

22. Ykp3089ykp3089

23. Dtxsid001027948

24. Ex-a3604

25. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, 2-carbamate, (alphar)-

26. Db06119

27. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Carbamate (ester), (alphar)-

28. Hy-17607

29. Cs-0014686

30. D11150

31. Q27286352

32. (1r)-1-(2-chlorophenyl)-2-(tetrazol-yl)ethyl)carbamate

33. (1r)-1-(2-chlorophenyl)-2-(2h-1,2,3,4-tetrazol-2-yl)ethyl Carbamate

34. (1r)-1-(2-chlorophenyl)-2-(2h-tetrazol-2-yl)ethyl Carbamate

35. 2h-tetrazole-2-ethanol, .alpha.-(2-chlorophenyl)-, 2-carbamate, (.alpha.r)-

36. 2h-tetrazole-2-ethanol, .alpha.-(2-chlorophenyl)-, Carbamate (ester), (.alpha.r)-

37. 2h-tetrazole-2-ethanol, Alpha-(2-chlorophenyl)-, Yl)ethyl)carbamate Carbamate (ester), (.alpha.r)-

2.4 Create Date
2006-12-11
3 Chemical and Physical Properties
Molecular Weight 267.67 g/mol
Molecular Formula C10H10ClN5O2
XLogP31.5
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Exact Mass267.0523023 g/mol
Monoisotopic Mass267.0523023 g/mol
Topological Polar Surface Area95.9 Ų
Heavy Atom Count18
Formal Charge0
Complexity293
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Cenobamate is indicated for the treatment of partial onset seizures in adults.


Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.


5 Pharmacology and Biochemistry
5.1 Pharmacology

The mechanism of cenobamate is unknown, however it modulates GABAA and inhibit voltage gated sodium channels. Cenobamate is given once daily and so it has a long duration of action. The therapeutic window is wide as doses of 750mg can be well tolerated. Patients should be counselled regarding the risk of DRESS syndrome, QT interval shortening, suicidal behavior, and neurological adverse effects.


5.2 MeSH Pharmacological Classification

Anticonvulsants

Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)


5.3 ATC Code

N03AX


N - Nervous system

N03 - Antiepileptics

N03A - Antiepileptics

N03AX - Other antiepileptics

N03AX25 - Cenobamate


5.4 Absorption, Distribution and Excretion

Absorption

Cenobamate is 88% orally bioavailable with a Tmax of 1-4 hours. A high fat meal does not significantly impact the pharmacokinetics of cenobamate.


Route of Elimination

Cenobamate is 87.8% eliminated in the urine and 5.2% in the feces.


Volume of Distribution

The apparent volume of distribution of cenobamate is 40-50L.


Clearance

The apparent oral clearance of cenobamate is 0.45-0.63L/h for a 100-400mg/day dose.


5.5 Metabolism/Metabolites

Data regarding the metabolism of cenobamate is lacking, however it is mostly glucuronidated by UGT2B7 and UGT2B4 or oxidized by a number of cytochromes.


5.6 Biological Half-Life

The terminal half life of cenobamate is 50-60h.


5.7 Mechanism of Action

Cenobamate inhibits voltage gated sodium channels and is a positive GABAA modulator. However, the exact mechanism of action remains unknown. Inhibition of voltage gated sodium channels increases the threshold for generating action potentials and decreases the number of action potentials.


USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 40667

Submission : 2024-10-28

Status : Active

Type : II

Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2023-11-13

Pay. Date : 2023-09-28

DMF Number : 38780

Submission : 2023-09-21

Status : Active

Type : II

Biophore

03

BIO Partnering at JPM
Not Confirmed

03

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-11-13

Pay. Date : 2023-09-15

DMF Number : 38814

Submission : 2023-09-26

Status : Active

Type : II

blank

04

BIO Partnering at JPM
Not Confirmed

04

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-11-08

Pay. Date : 2023-09-29

DMF Number : 38751

Submission : 2023-09-20

Status : Active

Type : II

blank

05

BIO Partnering at JPM
Not Confirmed

05

BIO Partnering at JPM
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41155

Submission : 2025-03-28

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Cenobamate IH

Date of Issue : 2024-04-03

Valid Till : 2027-01-21

Written Confirmation Number : WC-0493

Address of the Firm : Unit-IV, Plot No: 34B, 40B & 60B, J.N. Pharma City, Thanam (V), Parawada (M), An...

Metrochem
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Cenobamate

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBiophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

Flag India
Digital Content Digital Content

Cenobamate

About the Company : Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&...

Biophore, founded in 2007, develops and manufactures niche and complex pharmaceutical products. With USFDA- and EU-approved API facilities, a dedicated intermediates site and an R&D center of 400 scientists, the company is a leading global API player. Biophore ranks among the top US DMF filers, holds 150+ patents and maintains a strong compliance record with major regulatory agencies. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Biophore

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMaithri Drugs: Dedicated to your API needs.

Flag India
Digital Content Digital Content

Cenobamate

About the Company : Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, ant...

Maithri Drugs Pvt. Ltd. is a global supplier of Active Pharmaceutical Ingredients (APIs), serving pharmaceutical companies in 60+ countries. Its API portfolio spans antivirals, antibiotics, ARVs, CNS, and cardiovascular segments. The company operates facilities approved by US FDA, EDQM, Health Canada, and WHO-GMP, supported by multiple global DMFs and Ecovadis recognition. Backed by strong R&D, global patents, and customer-focused practices, Maithri delivers high-quality APIs with regulatory excellence. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Company Banner

04

Allastir

India
BIO Partnering at JPM
Not Confirmed
arrow

Allastir

India
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : Allastir instituted the services in 2010 with a motive to cater the pharmaceutical industry with niche API's. In Allastir we strongly believe in team work and customer satisfaction...

Allastir instituted the services in 2010 with a motive to cater the pharmaceutical industry with niche API's. In Allastir we strongly believe in team work and customer satisfaction. Allastir is backed by the strong R&D team who are passionate about what they do. We manufacture niche API's with high quality which are suitable for formulations like tablets, capsules, soft gelatins and oral liquids.To be the larder to develop innovative niche molecule to the health care industry for the betterment of human life.Our Vision is to be the Number ONE company in Health care Industry in the World.
blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to G...

Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilities that adhere to GMP standards. We take great pride in producing top-notch intermediates through our fully backward-integrated process. Aptra Synthesis Private Limited (ASPL) stands as one of the rapidly emerging manufacturers of Active Pharmaceutical Ingredients (APIs), Pellets (Semi-finished Formulations), and Intermediates.
blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness. Bajaj Healt...

Bajaj Healthcare Ltd. is a company established in 1993, services various Pharmaceuticals, Nutraceutical and Food industries globally with a spirit of scrupulousness. Bajaj Healthcare Ltd. have metamorphosed into specialty company and focused on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries. Bajaj healthcare Ltd. in its shot life span has gained loyalty from national and international customers and our products enjoy good fame in the overseas market.
blank

07

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...

Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products in the market and in the pipeline, MSN has 6 API (including Oncology) and one finished dosage facilities (one more for Oncology is being built) and an integrated R&D Center for Contract Research And Manufacturing Services (CRAMS) located in Hyderabad. MSN has won the trust of more than 250 customers across 65 countries around the globe covering the US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. Our product basket offers 100 APIs
blank

08

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : Established in 1984, R L Fine Chem Pvt. Ltd. is one of the fastest growing API companies, with a leadership position in several APIs such as antihistamines, antidepressants and mus...

Established in 1984, R L Fine Chem Pvt. Ltd. is one of the fastest growing API companies, with a leadership position in several APIs such as antihistamines, antidepressants and muscle relaxants. Acquired by private equity groups in 2016, it is one of India’s leading manufacturers of psychotropic substances. It supplies over 60 APIs to customers in more than 62 countries from FDA and EU-approved locations. R L Fine Chem is a technology-driven company with a focus on the in-house manufacture of key intermediates for our APIs. The company currently operates out of four facilities in the Indian states of Karnataka and Andhra Pradesh.
blank

09

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : Sekhmet Pharmaventures Pvt. Ltd., an Indian subsidiary of Gamot API Pte. Ltd., is backed by prominent private equity firms including PAG, CX Partners, and Samara Capital. The compa...

Sekhmet Pharmaventures Pvt. Ltd., an Indian subsidiary of Gamot API Pte. Ltd., is backed by prominent private equity firms including PAG, CX Partners, and Samara Capital. The company has acquired majority stakes in Anjan Drug (2020) and Optimus Drugs (2022), and is investing in new manufacturing facilities focused on APIs and formulations. With this strategy, Sekhmet aims to become a leading integrated pharma platform, supporting India's growing role in the global supply chain.
blank

10

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

About the Company : SMS Pharmaceuticals Ltd. is a global player in API manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off as a sin...

SMS Pharmaceuticals Ltd. is a global player in API manufacturing having a strong research and manufacturing team supported by state of the art facilities. What started off as a single facility - single product manufacturing company in 1990 grew to be a multi-location group having product list spreading across an array of therapeutic segments. SMS was given the export house status in the year 1997-98. SMS is currently a listed company having ever appreciating international and domestic customer base.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1707244200,"product":"CENOBAMATE","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"RIYADH","customer":"SAUDI PHARMACEUTICALS INDUSTRIES","customerCountry":"SAUDI ARABIA","quantity":"36.78","actualQuantity":"36.78","unit":"KGS","unitRateFc":"2900","totalValueFC":"105390.3","currency":"USD","unitRateINR":237755.06797172377,"date":"07-Feb-2024","totalValueINR":"8744631.4","totalValueInUsd":"105390.3","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"7340314","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1708453800,"product":"CENOBAMATE","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"RIYADH","customer":"SAUDI PHARMACEUTICAL INDUSTRIES","customerCountry":"SAUDI ARABIA","quantity":"16.22","actualQuantity":"16.22","unit":"KGS","unitRateFc":"2900","totalValueFC":"46505.9","currency":"USD","unitRateINR":237901.85141800248,"date":"21-Feb-2024","totalValueINR":"3858768.03","totalValueInUsd":"46505.9","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"7698936","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728066600,"product":"CENOBAMATE","address":"PLOT NO. 193, HOUSE NO. 5-35\/50,","city":"HYDERABAD, AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"AVIXA ILAC SAN VE TIC AS","customerCountry":"TURKEY","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"3750","totalValueFC":"18435.6","currency":"USD","unitRateINR":309815.57999999996,"date":"05-Oct-2024","totalValueINR":"1549077.9","totalValueInUsd":"18435.6","indian_port":"Hyderabad Air","hs_no":"29331999","bill_no":"4585838","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 193, HOUSE NO. 5-35\/50,, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1728930600,"product":"CENOBAMATE IHS","address":"FLAT NO.302, BHANU ENCLAVE","city":"HYDERABAD.AP","supplier":"METROCHEM API PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"UNDISCLOSED","customerCountry":"ARGENTINA","quantity":"190.00","actualQuantity":"190","unit":"KGS","unitRateFc":"1850","totalValueFC":"345582.5","currency":"USD","unitRateINR":152832.12631578947,"date":"15-Oct-2024","totalValueINR":"29038104","totalValueInUsd":"345582.5","indian_port":"Hyderabad Air","hs_no":"29333990","bill_no":"4838393","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"FLAT NO.302, BHANU ENCLAVE, HYDERABAD.AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1730485800,"product":"CENOBAMATE(ACN)","address":"Sy.No.539\/LU,542\/A\/AA\/U\/UU,","city":"NALGONDA","supplier":"APICHEM LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY CO DUBAI","customerCountry":"UNITED ARAB EMIRATES","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"3960","totalValueFC":"7737.4","currency":"USD","unitRateINR":326474.5,"date":"02-Nov-2024","totalValueINR":"652949","totalValueInUsd":"7737.4","indian_port":"Hyderabad Air","hs_no":"29379090","bill_no":"5326980","productDescription":"API","marketType":"","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Sy.No.539\/LU,542\/A\/AA\/U\/UU,, NALGONDA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1745951400,"product":"PHARMACEUTICAL API:- CENOBAMATE","address":"5\/502, GARDEN ESTATE,","city":"THANE, MAHARASHTRA.","supplier":"AMTEC HEALTH CARE PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"HONG KONG","customer":"SANAGU LTD","customerCountry":"HONG KONG","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"7003","totalValueFC":"7370.4","currency":"EURO","unitRateINR":630916.65000000002,"date":"30-Apr-2025","totalValueINR":"630916.65","totalValueInUsd":"7370.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"1418707","productDescription":"API","marketType":"","country":"HONG KONG","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"5\/502, GARDEN ESTATE,, THANE, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1746210600,"product":"CENOBAMATE(ACN)","address":"Sy.No.539\/LU,542\/A\/AA\/U\/UU,","city":"NALGONDA","supplier":"APICHEM LABORATORIES PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"BASLE","customer":"AIRPHARM PRATTELN","customerCountry":"SWITZERLAND","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"3960","totalValueFC":"3819.6","currency":"USD","unitRateINR":325435,"date":"03-May-2025","totalValueINR":"325435","totalValueInUsd":"3819.6","indian_port":"Hyderabad Air","hs_no":"29379090","bill_no":"1507408","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Sy.No.539\/LU,542\/A\/AA\/U\/UU,, NALGONDA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1752431400,"product":"CENOBAMATE (EXPORT INVOICE NO : 6124010765 DT :29.03.2025)","address":"SYNO.257 258\/1, DNO.11-6\/56,","city":"VILLAGE BALANGAR POST HYDERABAD","supplier":"LEE PHARMA LTD","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES, BA","customer":"BALIARDA S A","customerCountry":"ARGENTINA","quantity":"10.00","actualQuantity":"10","unit":"KGS","unitRateFc":"2000","totalValueFC":"19385","currency":"USD","unitRateINR":166838.60000000001,"date":"14-Jul-2025","totalValueINR":"1668386","totalValueInUsd":"19385","indian_port":"Hyderabad Air","hs_no":"29335990","bill_no":"3554827","productDescription":"API","marketType":"","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"SYNO.257 258\/1, DNO.11-6\/56,, VILLAGE BALANGAR POST HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1754245800,"product":"CENOBAMATE","address":"PLOT NO. 193, HOUSE NO. 5-35\/50,","city":"HYDERABAD, AP","supplier":"BIOPHORE INDIA PHARMACEUTICALS PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"AMMAN","customer":"UNITED PHARMACEUTICALS","customerCountry":"JORDAN","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"2500","totalValueFC":"9669.8","currency":"USD","unitRateINR":211574.25,"date":"04-Aug-2025","totalValueINR":"846297","totalValueInUsd":"9669.8","indian_port":"Hyderabad Air","hs_no":"29331999","bill_no":"4163072","productDescription":"API","marketType":"","country":"JORDAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"PLOT NO. 193, HOUSE NO. 5-35\/50,, HYDERABAD, AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1757529000,"product":"CENOBAMATE","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"UNDISCLOSED","customerCountry":"TAIWAN","quantity":"8.00","actualQuantity":"8","unit":"KGS","unitRateFc":"2850","totalValueFC":"22437.7","currency":"USD","unitRateINR":247569.48624999999,"date":"11-Sep-2025","totalValueINR":"1980555.89","totalValueInUsd":"22437.7","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"5205546","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""}]
07-Feb-2024
11-Sep-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Bajaj is working on a generic version of the anti-seizure medication, cenobamate, as part of its efforts to expand its portfolio in the epilepsy treatment market.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Cenobamate-Generic

Study Phase: Phase IIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 20, 2025

blank

01

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Bajaj is working on a generic version of the anti-seizure medication, cenobamate, as part of its efforts to expand its portfolio in the epilepsy treatment market.

Product Name : Cenobamate-Generic

Product Type : Controlled Substance

Upfront Cash : Inapplicable

March 20, 2025

blank

Details:

Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Xcopri

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: SK Biopharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 20, 2025

blank

02

Dong-A ST Co., Ltd.

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Dong-A ST Co., Ltd.

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.

Product Name : Xcopri

Product Type : Controlled Substance

Upfront Cash : Inapplicable

February 20, 2025

blank

Details:

Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Xcopri

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: SK Biopharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 10, 2024

blank

03

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.

Product Name : Xcopri

Product Type : Controlled Substance

Upfront Cash : Inapplicable

December 10, 2024

blank

Details:

Ignis Therapeutics holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Greater China.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Xcopri

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: SK Biopharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 04, 2024

blank

04

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Ignis Therapeutics holds exclusive commercialization rights to Xcopri (cenobamate), is an antiseizure medication for epilepsy in Greater China.

Product Name : Xcopri

Product Type : Controlled Substance

Upfront Cash : Inapplicable

December 04, 2024

blank

Details:

Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Xcopri

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: SK Biopharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 08, 2024

blank

05

Eurofarma

Brazil
arrow
BIO Partnering at JPM
Not Confirmed

Eurofarma

Brazil
arrow
BIO Partnering at JPM
Not Confirmed

Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.

Product Name : Xcopri

Product Type : Controlled Substance

Upfront Cash : Inapplicable

October 08, 2024

blank

Details:

Cenobamate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epilepsies, Partial.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 19, 2024

blank

06

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Cenobamate is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Epilepsies, Partial.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

September 19, 2024

blank

Details:

Cenobamate is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy, Generalized.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 30, 2024

blank

07

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Cenobamate is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Epilepsy, Generalized.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

August 30, 2024

blank

Details:

Cenobamate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsy, Generalized.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 11, 2024

blank

08

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Cenobamate is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Epilepsy, Generalized.

Product Name : Undisclosed

Product Type : Controlled Substance

Upfront Cash : Inapplicable

June 11, 2024

blank

Details:

Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Xcopri

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 11, 2024

blank

09

SK Biopharmaceuticals

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

SK Biopharmaceuticals

South Korea
arrow
BIO Partnering at JPM
Not Confirmed

Details : Xcopri (cenobamate), is an antiseizure medication (ASM) for adults with partial-onset (focal) seizures, is now approved as oral suspension or can be administered via a nasogastric tube.

Product Name : Xcopri

Product Type : Controlled Substance

Upfront Cash : Inapplicable

April 11, 2024

blank

Details:

Xcopri (cenobamate) is a positive allosteric modulator of the GABAA ion channel. It is approved as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy.


Lead Product(s): Cenobamate,Inapplicable

Therapeutic Area: Neurology Brand Name: Xcopri

Study Phase: Approved FDFProduct Type: Controlled Substance

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 22, 2024

blank

10

BIO Partnering at JPM
Not Confirmed
BIO Partnering at JPM
Not Confirmed

Details : Xcopri (cenobamate) is a positive allosteric modulator of the GABAA ion channel. It is approved as adjunctive therapy in the management of partial-onset seizures in adults with epilepsy.

Product Name : Xcopri

Product Type : Controlled Substance

Upfront Cash : Inapplicable

January 22, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

06

SK LIFE

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

SK LIFE

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

CENOBAMATE

Brand Name : XCOPRI

Dosage Form : TABLET;ORAL

Dosage Strength : 12.5MG

Approval Date : 2020-03-10

Application Number : 212839

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

07

SK LIFE

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

SK LIFE

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

CENOBAMATE

Brand Name : XCOPRI

Dosage Form : TABLET;ORAL

Dosage Strength : 25MG

Approval Date : 2020-03-10

Application Number : 212839

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

08

SK LIFE

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

SK LIFE

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

CENOBAMATE

Brand Name : XCOPRI

Dosage Form : TABLET;ORAL

Dosage Strength : 50MG

Approval Date : 2020-03-10

Application Number : 212839

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

09

SK LIFE

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

SK LIFE

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

CENOBAMATE

Brand Name : XCOPRI

Dosage Form : TABLET;ORAL

Dosage Strength : 100MG

Approval Date : 2020-03-10

Application Number : 212839

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

10

SK LIFE

U.S.A
BIO Partnering at JPM
Not Confirmed
arrow

SK LIFE

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

CENOBAMATE

Brand Name : XCOPRI

Dosage Form : TABLET;ORAL

Dosage Strength : 150MG

Approval Date : 2020-03-10

Application Number : 212839

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamat

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 200mg

Packaging :

Approval Date : 26/03/2021

Application Number : 20200312000079

Regulatory Info : Approved

Registration Country : Sweden

blank

02

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Monastery

Brand Name : Ontozry

Dosage Form : Tablet

Dosage Strength : 12.5mg

Packaging :

Approval Date : 19/05/2022

Application Number : 68051

Regulatory Info : Allowed

Registration Country : Switzerland

blank

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Monastery

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 50mg

Packaging :

Approval Date : 19/05/2022

Application Number : 68051

Regulatory Info : Allowed

Registration Country : Switzerland

blank

04

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Monastery

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 150mg

Packaging :

Approval Date : 19/05/2022

Application Number : 68051

Regulatory Info : Allowed

Registration Country : Switzerland

blank

05

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Monastery

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 200mg

Packaging :

Approval Date : 19/05/2022

Application Number : 68051

Regulatory Info : Allowed

Registration Country : Switzerland

blank

06

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 100MG

Packaging :

Approval Date : 2021-06-02

Application Number : 1211530005

Regulatory Info : Authorized

Registration Country : Spain

blank

07

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 150MG

Packaging :

Approval Date : 2024-09-18

Application Number : 1211530009IP

Regulatory Info : Authorized

Registration Country : Spain

blank

08

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 50MG

Packaging :

Approval Date : 2021-06-02

Application Number : 1211530002

Regulatory Info : Authorized

Registration Country : Spain

blank

09

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Cenobamate

Brand Name : Ontozry

Dosage Form : Film Coated Tablet

Dosage Strength : 50MG

Packaging :

Approval Date : 2025-01-23

Application Number : 1211530002IP

Regulatory Info : Authorized

Registration Country : Spain

blank

10

Orifarm AS

Denmark
BIO Partnering at JPM
Not Confirmed
arrow

Orifarm AS

Denmark
arrow
BIO Partnering at JPM
Not Confirmed

Senobamat

Brand Name : Ontozory

Dosage Form : Tablet, film-coated

Dosage Strength : 200 mg

Packaging : Blisterpakning 28item

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 913088-80-9 / Cenobamate API manufacturers, exporters & distributors?

Cenobamate manufacturers, exporters & distributors 1

89

PharmaCompass offers a list of Cenobamate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cenobamate manufacturer or Cenobamate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cenobamate manufacturer or Cenobamate supplier.

PharmaCompass also assists you with knowing the Cenobamate API Price utilized in the formulation of products. Cenobamate API Price is not always fixed or binding as the Cenobamate Price is obtained through a variety of data sources. The Cenobamate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Cenobamate

Synonyms

Xcopri, 913088-80-9, Cenobamate [inn], Ykp3089, Ykp-3089, P85x70rzws

Cas Number

913088-80-9

Unique Ingredient Identifier (UNII)

P85X70RZWS

About Cenobamate

Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.

Cenobamate Manufacturers

A Cenobamate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cenobamate, including repackagers and relabelers. The FDA regulates Cenobamate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cenobamate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cenobamate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cenobamate Suppliers

A Cenobamate supplier is an individual or a company that provides Cenobamate active pharmaceutical ingredient (API) or Cenobamate finished formulations upon request. The Cenobamate suppliers may include Cenobamate API manufacturers, exporters, distributors and traders.

click here to find a list of Cenobamate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cenobamate USDMF

A Cenobamate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cenobamate active pharmaceutical ingredient (API) in detail. Different forms of Cenobamate DMFs exist exist since differing nations have different regulations, such as Cenobamate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cenobamate DMF submitted to regulatory agencies in the US is known as a USDMF. Cenobamate USDMF includes data on Cenobamate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cenobamate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cenobamate suppliers with USDMF on PharmaCompass.

Cenobamate KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Cenobamate Drug Master File in Korea (Cenobamate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cenobamate. The MFDS reviews the Cenobamate KDMF as part of the drug registration process and uses the information provided in the Cenobamate KDMF to evaluate the safety and efficacy of the drug.

After submitting a Cenobamate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cenobamate API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Cenobamate suppliers with KDMF on PharmaCompass.

Cenobamate WC

A Cenobamate written confirmation (Cenobamate WC) is an official document issued by a regulatory agency to a Cenobamate manufacturer, verifying that the manufacturing facility of a Cenobamate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cenobamate APIs or Cenobamate finished pharmaceutical products to another nation, regulatory agencies frequently require a Cenobamate WC (written confirmation) as part of the regulatory process.

click here to find a list of Cenobamate suppliers with Written Confirmation (WC) on PharmaCompass.

Cenobamate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cenobamate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cenobamate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cenobamate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cenobamate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cenobamate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cenobamate suppliers with NDC on PharmaCompass.

Cenobamate GMP

Cenobamate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cenobamate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cenobamate GMP manufacturer or Cenobamate GMP API supplier for your needs.

Cenobamate CoA

A Cenobamate CoA (Certificate of Analysis) is a formal document that attests to Cenobamate's compliance with Cenobamate specifications and serves as a tool for batch-level quality control.

Cenobamate CoA mostly includes findings from lab analyses of a specific batch. For each Cenobamate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cenobamate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cenobamate EP), Cenobamate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cenobamate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty